Mesoblast (ASX:MSB) talks disruptive cellular medicines

0
35



Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company’s Phase 3 trials, its agreement with Tasly China and the near-term potential of stem cell medicines.